Loading…
Kyntra Bio, Inc. is projected to rise to $7.96 by 2027, a +18% move from its current price of $6.76. KYNB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $6.62 | $6.76 | $6.91 | +0.06% |
| Aug 6 | $6.56 | $6.77 | $6.98 | +0.12% |
| Aug 7 | $6.52 | $6.77 | $7.04 | +0.18% |
| Aug 8 | $6.48 | $6.78 | $7.08 | +0.24% |
| Aug 9 | $6.45 | $6.78 | $7.12 | +0.30% |
| Aug 10 | $6.43 | $6.78 | $7.16 | +0.36% |
| Aug 11 | $6.40 | $6.79 | $7.20 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.40 | $6.79 | $7.20 | +0.42% |
| Week 2 | $6.28 | $6.82 | $7.40 | +0.84% |
| Week 3 | $6.19 | $6.85 | $7.57 | +1.26% |
| Week 4 | $6.12 | $6.87 | $7.72 | +1.68% |
| Week 5 | $6.06 | $6.90 | $7.86 | +2.11% |
| Week 6 | $6.01 | $6.93 | $8.00 | +2.54% |
| Week 7 | $5.96 | $6.96 | $8.12 | +2.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kyntra Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Kyntra Bio has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Kyntra Bio, Inc. trades under the symbol KYNB and is currently priced at $6.98.
The company has a market capitalization of $28.24M and is ranked 4550. These metrics place the stock among smaller-cap healthcare names with significant research and development activity.
The forecasted price outlook shows an increasing average price path across the coming years, with an average of $6.98 in 2026 rising to higher levels later on. Notable milestones include an average of $9.12 in 2030 and $35.84 in 2050, with ROIs advancing to 30.7% in 2030 and 413.9% in 2050. The longer-term view suggests bullish momentum in the later years along with substantial upside.
A major floor 9.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.9% away) — a key level to hold.
The nearest ceiling, 12.9% above — a clean break opens room to run.
A major ceiling 17.6% above — clearing it would confirm fresh momentum.
Key KYNB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KYNB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.87 | Sell | $6.85 | Sell |
| MA 10 | $7.00 | Sell | $6.97 | Sell |
| MA 20 | $7.18 | Sell | $7.07 | Sell |
| MA 50 | $7.05 | Sell | $7.10 | Sell |
| MA 100 | $7.05 | Sell | $7.27 | Sell |
| MA 200 | $7.97 | Sell | $8.07 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.67 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -150.81 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -6.66 | Sell |
| Bollinger %B (20,2) | 0.03 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.01 | Sell |
| Awesome (5,34) | -0.29 | Sell |
| Ultimate (7,14,28) | 18.64 | Buy |
| Momentum (10) | -0.50 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 6.72 | Buy |
| ADX (14) | 12.37 | Neutral |
| ATR (14) | 0.12 | Info |
The near-term technical picture is BEARISH.
RSI14 is 50, with the 50-day simple moving average at $7.06 and the 200-day simple moving average at $8.08. Price appears to be trading near support at $6.70 and facing resistance at $7.63. Over the last 30 days, the price range has been from a low of $6.03 to a high of $8.07.
Annualized volatility stands at 40%, underscoring the potential for sizable moves in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.46 | $6.76 | $9.22 | 0% | Neutral | |
| $6.46 | $7.96 | $10.29 | +18% | Neutral | |
| $6.21 | $7.83 | $10.44 | +16% | Neutral | |
| $6.74 | $8.64 | $11.82 | +28% | Bullish | |
| $6.71 | $8.75 | $12.21 | +29% | Bullish | |
| $7.12 | $9.42 | $13.40 | +39% | Bullish | |
| $8.50 | $11.40 | $16.47 | +69% | Bullish | |
| $8.89 | $12.08 | $17.71 | +79% | Bullish | |
| $9.46 | $13.00 | $19.32 | +92% | Bullish | |
| $9.70 | $13.48 | $20.29 | +99% | Bullish | |
| $13.17 | $19.27 | $30.58 | +185% | Bullish | |
| $20.96 | $33.42 | $57.33 | +394% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $6.46 | $6.76 | $8.29 | +0.00% |
| September 2026 | $6.09 | $7.16 | $8.62 | +5.87% |
| October 2026 | $6.04 | $7.14 | $8.68 | -0.26% |
| November 2026 | $6.08 | $7.23 | $8.85 | +1.24% |
| December 2026 | $6.27 | $7.48 | $9.22 | +3.55% |
Click any year to see its month-by-month KYNB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Kyntra Bio, Inc.'s 2026 outlook centres on $6.76, within a $6.46 to $9.22 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, KYNB could reach as high as $10.29, with a base case around $7.96 and support toward $6.46 — roughly +18% from $6.76. Price action looks broadly range-bound.
Expect KYNB to range from $6.21 to $10.44 through 2028. The $7.83 average target implies a +16% move from current prices. That is -2% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The KYNB price prediction for 2029 points to an average of $8.64 (low $6.74, high $11.82) — a potential gain of +28% on today's $6.76. Momentum favours further upside here.
In 2030, KYNB is projected to trade between $6.71 and $12.21, averaging $8.75 — a potential gain of +29% from today's $6.76. That is up +1% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Kyntra Bio, Inc.'s 2031 outlook centres on $9.42, within a $7.12 to $13.40 range. That is up +8% on the projected 2030 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2032, KYNB could reach as high as $16.47, with a base case around $11.40 and support toward $8.50 — roughly +69% from $6.76. Buyers look set to stay in control over this stretch.
Expect KYNB to range from $8.89 to $17.71 through 2033. The $12.08 average target implies a +79% move from current prices. That is up +6% on the projected 2032 average. Momentum favours further upside here.
The KYNB price prediction for 2034 points to an average of $13.00 (low $9.46, high $19.32) — a potential gain of +92% on today's $6.76. Buyers look set to stay in control over this stretch.
In 2035, KYNB is projected to trade between $9.70 and $20.29, averaging $13.48 — a potential gain of +99% from today's $6.76. That is up +4% on the projected 2034 average. Momentum favours further upside here.
Kyntra Bio, Inc.'s 2040 outlook centres on $19.27, within a $13.17 to $30.58 range. That is up +43% on the projected 2035 average. That marks a +185% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, KYNB could reach as high as $57.33, with a base case around $33.42 and support toward $20.96 — roughly +394% from $6.76. Momentum favours further upside here.
Investing $1,000 in KYNB today (≈ 147.928994 KYNB) could be worth
$4,944.04
+$3,944.04 (+394%) by 2050 · US Dollar
Based on the average projected KYNB price of $33.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KYNBwould be worth at today's price.
$1,000 invested in KYNB on Jul 31, 2025 (≈ 144.508669 KYNB) would be worth
$976.88
-$23.12 (-2.3%) today · 0.98× · US Dollar
Based on a KYNB entry price of $6.92 vs. today's $6.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.03 | $961.59 | -3.8% |
| 1 month ago | $7.55 | $895.36 | -10.5% |
| 3 months ago | $7.09 | $953.46 | -4.7% |
| 6 months ago | $8.16 | $828.43 | -17.2% |
| 1 year ago | $6.92 | $976.88 | -2.3% |
| All time (5.0y) ago | $346 | $19.54 | -98.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KYNB forecast.
Our base-case forecast reaches $14.00 around 2040.
Implied market cap at $14.00: $56.67M
Looking at the multi-year forecast, the average price climbs through the decades with expanding upside. The 2026 average is $6.98, rising to $8.20 in 2027 and $8.14 in 2028, then steadily higher to $9.04 in 2029 and $9.12 in 2030. By 2031 the average is $9.92, and 2032 reaches $12.05, followed by $12.69 in 2033 and $13.74 in 2034.
The trajectory continues to $14.26 in 2035, then jumps to $20.54 in 2040 and $35.84 in 2050.
ROI percentages rise along the path: 0% in 2026, 17.6% in 2027, 16.7% in 2028, 29.6% in 2029, 30.7% in 2030, 42.2% in 2031, 72.8% in 2032, 81.9% in 2033, 97% in 2034, 104.4% in 2035, 194.5% in 2040, and 413.9% in 2050. Sentiment is NEUTRAL for 2026–2028 and BULLISH from 2029 onward.
These are estimates, not guarantees, and actual outcomes may differ. The numbers illustrate potential upside over a long horizon while acknowledging inherent investment uncertainties.
Tap a question to reveal the answer.
Average price in 2030 is $9.12 with a min of $6.99 and a max of $12.73, and an estimated ROI of 30.7%. The sentiment is BULLISH for 2030.
Forecasts show a transition from NEUTRAL in 2026–2028 to BULLISH from 2029 onward, with an average price of $9.12 in 2030 and a 2050 average of $35.84, corresponding to a 413.9% ROI in 2050. These are estimates, not guarantees.
Yes. The 2040 forecast shows an average price of $20.54 with a max of $32.61 and a min of $14.03, and a 2040 ROI of 194.5%.
The current price is $6.98 and the market capitalization is $28.24M.
The 30-day range is $6.03 to $8.07.
Kyntra Bio, Inc. Community Discussion
0Share your Kyntra Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.